-
Je něco špatně v tomto záznamu ?
Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project
M. Deloria Knoll, JC. Bennett, M. Garcia Quesada, EW. Kagucia, ME. Peterson, DR. Feikin, AL. Cohen, MK. Hetrich, Y. Yang, JN. Sinkevitch, K. Ampofo, L. Aukes, S. Bacci, G. Bigogo, MC. Brandileone, MG. Bruce, R. Camilli, J. Castilla, G. Chan, G....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
001
World Health Organization - International
INV-010429 / OPP1189065
Bill and Melinda Gates Foundation
NLK
Directory of Open Access Journals
od 2013
PubMed Central
od 2013
Europe PubMed Central
od 2013
ProQuest Central
od 2013-01-01
Open Access Digital Library
od 2013-01-01
Open Access Digital Library
od 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
- Publikační typ
- časopisecké články MeSH
Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.
Centre for Disease Control Department of Health and Community Services Darwin City NT 8000 Australia
Centre for Disease Prevention and Control of Latvia 1005 Riga Latvia
Centre for Global Health Research Kenya Medical Research Institute P O Box 1578 40100 Kisumu Kenya
Child Health Research Foundation Dhaka 1207 Bangladesh
CIBER Epidemiología y Salud Pública 28029 Madrid Spain
Communicable Diseases Centre National Institute of Public Health 1000 Ljubljana Slovenia
Department of Health Security Finnish Institute for Health and Welfare 00271 Helsinki Finland
Department of Infection Control and Vaccine Norwegian Institute of Public Health 0456 Oslo Norway
Department of Infectious Diseases Italian National Institute of Health 00161 Rome Italy
Department of Microbiology Immunology and Transplantation KU Leuven 3000 Leuven Belgium
Department of Pediatrics University of Calgary and Alberta Health Services Calgary AB T3B 6A8 Canada
Department of Pediatrics Yale New Haven Children's Hospital New Haven CT 06504 USA
Department of Social and Preventive Medicine Laval University Québec QC G1V 0A6 Canada
Doctoral Studies Department Riga Stradinš University 1007 Riga Latvia
Epidemiology Department Dirección General de Salud Pública 28009 Madrid Spain
Epidemiology Department Epiconcept 75012 Paris France
European Centre for Disease Prevention and Control 169 73 Solna Sweden
Health Sciences Unit Faculty of Social Sciences Tampere University 33100 Tampere Finland
Immunisation and Countermeasures Division Public Health England London NW9 5EQ UK
Independent Consultant 1296 Coppet Switzerland
Infectious Disease Epidemiology and Prevention Statens Serum Institut DK 2300 Copenhagen Denmark
Instituto de Salud Pública de Chile Santiago 7780050 Santiago Metropolitan Chile
Instituto de Salud Pública de Navarra IdiSNA 31003 Pamplona Spain
Johns Hopkins Bloomberg School of Public Health Baltimore MD 21205 USA
Laboratorio Central de Salud Pública Asunción Paraguay Asunción Paraguay
Malawi Liverpool Wellcome Trust Clinical Research Programme P O Box 30096 Chichiri Blantyre Malawi
Ministry of Health and Medical Services Suva Fiji
National Institute for Public Health and the Environment 3721 MA Bilthoven The Netherlands
National Institute of Public Health 100 42 Praha Czech Republic
National Public Health Organisation 15123 Athens Greece
National Reference Centre for Bacterial Meningitis National Medicines Institute 00 725 Warsaw Poland
New Vaccines Group Murdoch Children's Research Institute Parkville Melbourne VIC 3052 Australia
Pan American Health Organization World Health Organization Washington DC 20037 USA
Santé Publique France the French National Public Health Agency FR 94410 Saint Maurice France
Singapore Ministry of Health Communicable Diseases Division Singapore 308442 Singapore
The Faculty of Health Sciences Ben Gurion University of the Negev 8410501 Beer Sheva Israel
Toyama Institute of Health Imizu Toyama 939 0363 Japan
Vaccine Study Center Kaiser Permanente Oakland CA 94612 USA
World Health Organization 1202 Geneva Switzerland
World Health Organization Regional Office for Africa P O Box 06 Brazzaville Congo
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21018033
- 003
- CZ-PrNML
- 005
- 20210729104112.0
- 007
- ta
- 008
- 210726s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/microorganisms9040742 $2 doi
- 035 __
- $a (PubMed)33918127
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Deloria Knoll, Maria $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 245 10
- $a Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project / $c M. Deloria Knoll, JC. Bennett, M. Garcia Quesada, EW. Kagucia, ME. Peterson, DR. Feikin, AL. Cohen, MK. Hetrich, Y. Yang, JN. Sinkevitch, K. Ampofo, L. Aukes, S. Bacci, G. Bigogo, MC. Brandileone, MG. Bruce, R. Camilli, J. Castilla, G. Chan, G. Chanto Chacón, P. Ciruela, H. Cook, M. Corcoran, R. Dagan, K. Danis, S. de Miguel, P. De Wals, S. Desmet, Y. Galloway, T. Georgakopoulou, LL. Hammitt, M. Hilty, PL. Ho, S. Jayasinghe, JD. Kellner, J. Kleynhans, MJ. Knol, J. Kozakova, KG. Kristinsson, SN. Ladhani, CS. Lara, ME. León, T. Lepp, GA. Mackenzie, L. Mad'arová, A. McGeer, T. Mungun, JM. Mwenda, JP. Nuorti, N. Nzoyikorera, K. Oishi, LH. De Oliveira, M. Paragi, T. Pilishvili, R. Puentes, E. Rafai, SK. Saha, L. Savrasova, C. Savulescu, JA. Scott, KJ. Scott, F. Serhan, LP. Setchanova, N. Sinkovec Zorko, A. Skoczyńska, TD. Swarthout, P. Valentiner-Branth, M. van der Linden, DF. Vestrheim, A. von Gottberg, I. Yildirim, K. Hayford, . The Pserenade Team
- 520 9_
- $a Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bennett, Julia C $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Garcia Quesada, Maria $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Kagucia, Eunice W $u Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
- 700 1_
- $a Peterson, Meagan E $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Feikin, Daniel R $u Independent Consultant, 1296 Coppet, Switzerland
- 700 1_
- $a Cohen, Adam L $u World Health Organization, 1202 Geneva, Switzerland
- 700 1_
- $a Hetrich, Marissa K $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Yang, Yangyupei $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Sinkevitch, Jenna N $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a Ampofo, Krow $u Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
- 700 1_
- $a Aukes, Laurie $u Vaccine Study Center, Kaiser Permanente, Oakland, CA 94612, USA
- 700 1_
- $a Bacci, Sabrina $u European Centre for Disease Prevention and Control, 169 73 Solna, Sweden
- 700 1_
- $a Bigogo, Godfrey $u Centre for Global Health Research, Kenya Medical Research Institute, P.O. Box 1578-40100, Kisumu, Kenya
- 700 1_
- $a Brandileone, Maria-Cristina C $u National Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz (IAL), São Paulo 01246-902, Brazil
- 700 1_
- $a Bruce, Michael G $u Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK 99508, USA
- 700 1_
- $a Camilli, Romina $u Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), 00161 Rome, Italy
- 700 1_
- $a Castilla, Jesús $u CIBER Epidemiología y Salud Pública, (CIBERESP), 28029 Madrid, Spain $u Instituto de Salud Pública de Navarra-IdiSNA, 31003 Pamplona, Spain
- 700 1_
- $a Chan, Guanhao $u Singapore Ministry of Health, Communicable Diseases Division, Singapore 308442, Singapore
- 700 1_
- $a Chanto Chacón, Grettel $u Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Tres Ríos, 30301 Cartago, Costa Rica
- 700 1_
- $a Ciruela, Pilar $u CIBER Epidemiología y Salud Pública, (CIBERESP), 28029 Madrid, Spain $u Surveillance and Public Health Emergency Response, Public Health Agency of Catalonia, 08005 Barcelona, Spain
- 700 1_
- $a Cook, Heather $u Centre for Disease Control, Department of Health and Community Services, Darwin City, NT 8000, Australia
- 700 1_
- $a Corcoran, Mary $u Irish Meningitis and Sepsis Reference Laboratory, Children's Health Ireland at Temple Street, Temple Street, D01 YC76 Dublin 1, Ireland
- 700 1_
- $a Dagan, Ron $u The Faculty of Health Sciences, Ben-Gurion University of the Negev, 8410501 Beer-Sheva, Israel
- 700 1_
- $a Danis, Kostas $u Santé Publique France, the French National Public Health Agency, FR-94410 Saint Maurice, France
- 700 1_
- $a de Miguel, Sara $u Epidemiology Department, Dirección General de Salud Pública, 28009 Madrid, Spain
- 700 1_
- $a De Wals, Philippe $u Department of Social and Preventive Medicine, Laval University, Québec, QC G1V 0A6, Canada
- 700 1_
- $a Desmet, Stefanie $u Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium $u National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, 3000 Leuven, Belgium
- 700 1_
- $a Galloway, Yvonne $u Epidemiology Team, Institute of Environmental Science and Research, Porirua, Wellington 5022, New Zealand
- 700 1_
- $a Georgakopoulou, Theano $u National Public Health Organisation, 15123 Athens, Greece
- 700 1_
- $a Hammitt, Laura L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA $u Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
- 700 1_
- $a Hilty, Markus $u Swiss National Reference Centre for invasive Pneumococci, Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland
- 700 1_
- $a Ho, Pak-Leung $u Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
- 700 1_
- $a Jayasinghe, Sanjay $u National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia
- 700 1_
- $a Kellner, James D $u Department of Pediatrics, University of Calgary, and Alberta Health Services, Calgary, AB T3B 6A8, Canada
- 700 1_
- $a Kleynhans, Jackie $u Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2192, South Africa $u School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg 2000, South Africa
- 700 1_
- $a Knol, Mirjam J $u National Institute for Public Health and the Environment, 3721 MA Bilthoven, The Netherlands
- 700 1_
- $a Kozakova, Jana $u National Institute of Public Health (NIPH), 100 42 Praha, Czech Republic
- 700 1_
- $a Kristinsson, Karl Gústaf $u Department of Clinical Microbiology, Landspitali-The National University Hospital, Hringbraut, 101 Reykjavik, Iceland
- 700 1_
- $a Ladhani, Shamez N $u Immunisation and Countermeasures Division, Public Health England, London NW9 5EQ, UK
- 700 1_
- $a Lara, Claudia S $u Servicio de Bacteriología Clínica, Departamento de Bacteriología, INEI-ANLIS "Dr. Carlos G. Malbrán", Buenos Aires C1282 AFF, Argentina
- 700 1_
- $a León, Maria Eugenia $u Laboratorio Central de Salud Pública, Asunción, Paraguay (Central Laboratory of Public Health, Asunción, Paraguay), Asunción, Paraguay
- 700 1_
- $a Lepp, Tiia $u Department of Communicable Disease and Control and Health Protection, Public Health Agency of Sweden, 171 82 Solna, Sweden
- 700 1_
- $a Mackenzie, Grant A $u Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK $u Medical Research Council Unit the Gambia at London School of Hygiene & Tropical Medicine, P.O. Box 273, Banjul, The Gambia $u New Vaccines Group, Murdoch Children's Research Institute, Parkville, Melbourne, VIC 3052, Australia
- 700 1_
- $a Mad'arová, Lucia $u National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, 975 56 Banská Bystrica, Slovakia
- 700 1_
- $a McGeer, Allison $u Toronto Invasive Bacterial Diseases Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
- 700 1_
- $a Mungun, Tuya $u National Center of Communicable Diseases (NCCD), Ministry of Health, Bayanzurkh District, Ulaanbaatar 13336, Mongolia
- 700 1_
- $a Mwenda, Jason M $u World Health Organization Regional Office for Africa, P.O. Box 06, Brazzaville, Congo
- 700 1_
- $a Nuorti, J Pekka $u Department of Health Security, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland $u Health Sciences Unit, Faculty of Social Sciences, Tampere University, 33100 Tampere, Finland
- 700 1_
- $a Nzoyikorera, Néhémie $u Bacteriology-Virology and Hospital Hygiene Laboratory, Ibn Rochd University Hospital Centre, Casablanca 20250, Morocco $u Department of Microbiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca 20000, Morocco
- 700 1_
- $a Oishi, Kazunori $u Toyama Institute of Health, Imizu, Toyama 939-0363, Japan
- 700 1_
- $a De Oliveira, Lucia Helena $u Pan American Health Organization, World Health Organization, Washington, DC 20037, USA
- 700 1_
- $a Paragi, Metka $u Centre for Medical Microbiology, National Laboratory of Health, Environment and Food, 2000 Maribor, Slovenia
- 700 1_
- $a Pilishvili, Tamara $u National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
- 700 1_
- $a Puentes, Rodrigo $u Instituto de Salud Pública de Chile, Santiago 7780050, Santiago Metropolitan, Chile
- 700 1_
- $a Rafai, Eric $u Ministry of Health and Medical Services, Suva, Fiji
- 700 1_
- $a Saha, Samir K $u Child Health Research Foundation, Dhaka 1207, Bangladesh
- 700 1_
- $a Savrasova, Larisa $u Centre for Disease Prevention and Control of Latvia, 1005 Riga, Latvia $u Doctoral Studies Department, Riga Stradinš University, 1007 Riga, Latvia
- 700 1_
- $a Savulescu, Camelia $u Epidemiology Department, Epiconcept, 75012 Paris, France
- 700 1_
- $a Scott, J Anthony $u Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
- 700 1_
- $a Scott, Kevin J $u Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, NHS GG&C, Glasgow, G31 2ER, UK
- 700 1_
- $a Serhan, Fatima $u World Health Organization, 1202 Geneva, Switzerland
- 700 1_
- $a Setchanova, Lena Petrova $u Department of Medical Microbiology, Medical University of Sofia, Faculty of Medicine, 1431 Sofia, Bulgaria
- 700 1_
- $a Sinkovec Zorko, Nadja $u Communicable Diseases Centre, National Institute of Public Health, 1000 Ljubljana, Slovenia
- 700 1_
- $a Skoczyńska, Anna $u National Reference Centre for Bacterial Meningitis, National Medicines Institute, 00-725 Warsaw, Poland
- 700 1_
- $a Swarthout, Todd D $u Malawi-Liverpool-Wellcome Trust Clinical Research Programme, P.O. Box 30096, Chichiri, Blantyre, Malawi $u NIHR Global Health Research Unit on Mucosal Pathogens, Division of Infection and Immunity, UCL, Bloomsbury, London WC1E 6BT, UK
- 700 1_
- $a Valentiner-Branth, Palle $u Infectious Disease Epidemiology and Prevention, Statens Serum Institut, DK-2300 Copenhagen, Denmark
- 700 1_
- $a van der Linden, Mark $u National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, 52074 Aachen, Germany
- 700 1_
- $a Vestrheim, Didrik F $u Department of Infection Control and Vaccine, Norwegian Institute of Public Health, 0456 Oslo, Norway
- 700 1_
- $a von Gottberg, Anne $u Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2192, South Africa $u School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg 2000, South Africa
- 700 1_
- $a Yildirim, Inci $u Department of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT 06504, USA
- 700 1_
- $a Hayford, Kyla $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
- 700 1_
- $a The Pserenade Team,
- 773 0_
- $w MED00198767 $t Microorganisms $x 2076-2607 $g Roč. 9, č. 4 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33918127 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104111 $b ABA008
- 999 __
- $a ind $b bmc $g 1676505 $s 1138475
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 9 $c 4 $e 20210402 $i 2076-2607 $m Microorganisms $n Microorganisms $x MED00198767
- GRA __
- $a 001 $p World Health Organization $2 International
- GRA __
- $a INV-010429 / OPP1189065 $p Bill and Melinda Gates Foundation
- LZP __
- $a Pubmed-20210726
